CN110251511A - 无免疫抑制活性的维持神经再生活性的fk506衍生物及其用途 - Google Patents

无免疫抑制活性的维持神经再生活性的fk506衍生物及其用途 Download PDF

Info

Publication number
CN110251511A
CN110251511A CN201910404660.9A CN201910404660A CN110251511A CN 110251511 A CN110251511 A CN 110251511A CN 201910404660 A CN201910404660 A CN 201910404660A CN 110251511 A CN110251511 A CN 110251511A
Authority
CN
China
Prior art keywords
deoxy
activity
demethyl
prolyl
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910404660.9A
Other languages
English (en)
Chinese (zh)
Inventor
尹汝准
权浩政
潘娟姬
S·普拉莫德布
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yin Terong Biotech Inc
Original Assignee
Yin Terong Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yin Terong Biotech Inc filed Critical Yin Terong Biotech Inc
Publication of CN110251511A publication Critical patent/CN110251511A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CN201910404660.9A 2014-08-01 2015-07-31 无免疫抑制活性的维持神经再生活性的fk506衍生物及其用途 Pending CN110251511A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2014-0099210 2014-08-01
KR1020140099210A KR101694879B1 (ko) 2014-08-01 2014-08-01 면역억제활성 없이 신경재생활성이 유지되는 fk506 유도체 및 그의 용도
CN201580041277.1A CN106794169B (zh) 2014-08-01 2015-07-31 无免疫抑制活性的维持神经再生活性的fk506衍生物及其用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580041277.1A Division CN106794169B (zh) 2014-08-01 2015-07-31 无免疫抑制活性的维持神经再生活性的fk506衍生物及其用途

Publications (1)

Publication Number Publication Date
CN110251511A true CN110251511A (zh) 2019-09-20

Family

ID=55217893

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910404660.9A Pending CN110251511A (zh) 2014-08-01 2015-07-31 无免疫抑制活性的维持神经再生活性的fk506衍生物及其用途
CN201580041277.1A Active CN106794169B (zh) 2014-08-01 2015-07-31 无免疫抑制活性的维持神经再生活性的fk506衍生物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580041277.1A Active CN106794169B (zh) 2014-08-01 2015-07-31 无免疫抑制活性的维持神经再生活性的fk506衍生物及其用途

Country Status (6)

Country Link
US (2) US10226446B2 (cg-RX-API-DMAC7.html)
EP (1) EP3187183B1 (cg-RX-API-DMAC7.html)
JP (2) JP6370490B2 (cg-RX-API-DMAC7.html)
KR (1) KR101694879B1 (cg-RX-API-DMAC7.html)
CN (2) CN110251511A (cg-RX-API-DMAC7.html)
WO (1) WO2016018117A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101694879B1 (ko) * 2014-08-01 2017-01-12 주식회사 인트론바이오테크놀로지 면역억제활성 없이 신경재생활성이 유지되는 fk506 유도체 및 그의 용도
CN113939519B (zh) * 2018-12-11 2025-02-14 莫尔根生物有限公司 促进毛发生长的新化合物及包含它们的组合物
US11449807B2 (en) 2020-01-31 2022-09-20 Walmart Apollo, Llc Systems and methods for bootstrapped machine learning algorithm training
WO2021256894A1 (ko) * 2020-06-19 2021-12-23 서울대학교 산학협력단 신경 돌기 생장 및 시냅스 형성 활성을 갖는 신규 prolylfk506 유도체 및 그의 용도
CN118460433B (zh) * 2024-06-04 2026-01-06 浙江启臻合成生物技术有限公司 生产他克莫司的链霉菌工程菌及其构建方法与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1997369A (zh) * 2004-05-12 2007-07-11 阿尔卡森制药有限公司 用于预防和/或治疗与靶向钙调神经磷酸酶有关疾病的阿片样受体拮抗剂化合物的应用
US20090325906A1 (en) * 2008-06-27 2009-12-31 Wendye Robbins Methods and compositions for therapeutic treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
MX2009006958A (es) * 2006-12-28 2009-07-09 Limerick Biopharma Inc Metodos y composiciones para tratamiento terapeutico.
KR101261131B1 (ko) 2010-08-24 2013-05-06 이화여자대학교 산학협력단 신규 타크롤리무스 유도체, 상기 유도체를 포함하는 신경 보호용 조성물, 상기 유도체를 포함하는 면역 억제용 조성물, 상기 유도체의 생산 방법 및 상기 유도체의 생산 균주
KR101632042B1 (ko) * 2014-06-30 2016-06-21 주식회사 인트론바이오테크놀로지 Fk506 유도체를 함유하는 크립토코쿠스 속 곰팡이 및 칸디다 속 곰팡이에 의한 진균 감염을 치료하기 위한 약제학적 조성물 및 그의 용도
KR101694879B1 (ko) * 2014-08-01 2017-01-12 주식회사 인트론바이오테크놀로지 면역억제활성 없이 신경재생활성이 유지되는 fk506 유도체 및 그의 용도

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1997369A (zh) * 2004-05-12 2007-07-11 阿尔卡森制药有限公司 用于预防和/或治疗与靶向钙调神经磷酸酶有关疾病的阿片样受体拮抗剂化合物的应用
US20090325906A1 (en) * 2008-06-27 2009-12-31 Wendye Robbins Methods and compositions for therapeutic treatment

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A SHAFIEE 等: "Chemical and biological characterization of two FK506 analogs produced by targeted gene disruption in Streptomyces sp. MA6548", 《J ANTIBIOT (TOKYO)》 *
BRUCE G GOLD: "Neuroimmunophilin ligands: evaluation of their therapeutic potential for the treatment of neurological disorders", 《EXPERT OPINION ON INVESTIGATIONAL DRUGS》 *
YEON HEE BAN等: "Characterization of FK506 biosynthetic intermediates involved in post-PKS elaboration", 《J. NAT. PROD.》 *

Also Published As

Publication number Publication date
EP3187183A1 (en) 2017-07-05
JP2017523241A (ja) 2017-08-17
US10226446B2 (en) 2019-03-12
WO2016018117A1 (ko) 2016-02-04
KR101694879B1 (ko) 2017-01-12
KR20160017267A (ko) 2016-02-16
EP3187183B1 (en) 2020-04-08
CN106794169B (zh) 2020-02-04
US20170216254A1 (en) 2017-08-03
EP3187183A4 (en) 2018-03-21
JP6851334B2 (ja) 2021-03-31
US20190134001A1 (en) 2019-05-09
JP6370490B2 (ja) 2018-08-08
US10576060B2 (en) 2020-03-03
JP2018083843A (ja) 2018-05-31
CN106794169A (zh) 2017-05-31

Similar Documents

Publication Publication Date Title
US10576060B2 (en) FK506 derivative maintaining nerve regeneration activity without immunosuppressive activity, and use thereof
KR101599982B1 (ko) 노노무라에아 종으로부터의 고리형 펩티드, 그에 대한 생산 프로세스 및 이를 포함하는 마이코박테리아 관련 질병의 치료 혹은 예방을 위한 약학적 조성물
EP3154534B1 (en) Small molecule efflux pump inhibitors
Stierle et al. Caspase-1 and 3 inhibiting drimane sesquiterpenoids from the extremophilic fungus, Penicillium solitum
CN103717222A (zh) 桥二硫二氧代哌嗪及其在治疗癌症方面的用途
CN1315863A (zh) 迷迭香酸及其衍生物用作免疫抑制剂或sh2介导过程的抑制剂
Goudou et al. Orbicularisine: a spiro-indolothiazine isolated from gills of the tropical bivalve Codakia orbicularis
KR101261131B1 (ko) 신규 타크롤리무스 유도체, 상기 유도체를 포함하는 신경 보호용 조성물, 상기 유도체를 포함하는 면역 억제용 조성물, 상기 유도체의 생산 방법 및 상기 유도체의 생산 균주
Ji et al. Macrocyclic nonapeptides incorporating uncharacterized amino acids with inhibitory effects on Th17 differentiation
TWI753912B (zh) 神經病症的治療
Son et al. Polyketides and anthranilic acid possessing 6-deoxy-α-L-talopyranose from a Streptomyces Species
Summers et al. 3-normeridamycin: a potent non-immunosuppressive immunophilin ligand is neuroprotective in dopaminergic neurons
KR102134782B1 (ko) 신규 화합물 및 이를 포함하는 신경계 질환 치료용 약학적 조성물
JP6791977B2 (ja) 骨格筋の肥大剤としてのフロスタン−3オール誘導体
KR20160067079A (ko) 면역억제활성 없이 신경재생활성이 유지되는 fk506 유도체 및 그의 용도
JP2002526540A (ja) 細胞毒性アルカロイド類(ハリツリン)
CN115916787B (zh) 具有神经突生长和突触形成活性的新型脯氨酰fk506衍生物及其用途
JPH0386822A (ja) 神経細胞変性修復剤
MX2013013863A (es) Antibioticos novedosos.
KR20250165858A (ko) Staphylococcus xylosus로부터 분리한 신규 피라지논 유도체 및 이의 용도
CN117769601A (zh) 化合物、其制造方法、抗菌剂和医药品
CN103374057B (zh) 一种对甘氨酸转运子具有抑制活性的化合物
Imae Studies on inhibitors of tumor-associated enzymes from marine sponges
Han Natural products studies of the marine cyanobacteria Lyngbya semiplena and Lyngbya majuscula
Marquez Structure and biosynthesis of marine cyanobacterial natural products: Development and application of new NMR methods

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20190920